Interplay Between NF-κB and Kruppel-like Factors in Vascular Inflammation and Atherosclerosis: Location, Location, Location

G. Brandon Atkins, MD, PhD; Daniel I. Simon, MD

Atherosclerosis is a highly complex process involving the dynamic interplay between cell types intrinsic (e.g., endothelial cells [ECs] and smooth muscle cells [SMCs]) and extrinsic (e.g., lymphocytes and myeloid cells) to the blood vessel wall. Over the last several decades extensive work has been conducted that details the many molecular pathways involved in mediating the pathologic vascular inflammation that occurs in atherosclerosis. One of the most important factors in the regulation of this process is the transcription factor nuclear factor κB (NF-κB). NF-κB has been shown to regulate numerous genes involved in the initiation and progression of atherosclerosis, including genes involved in inflammation and immune cell regulation as well as apoptosis and cell proliferation. Genetic approaches have been utilized to identify the different mechanisms and cell type intrinsic actions of NF-κB in mediating atherosclerosis and vascular inflammation. In providing a new example, Yoshida and colleagues investigate the cell autonomous role of NF-κB signaling in the pathogenesis of atherosclerosis, Gareus and colleagues generated different small mouse models employing either EC-specific ablation of NEMO/IKKγ to interfere with IKK activation or transgenic expression of degradation resistant dominant negative IκBα superrepressor (DNICα). EC-restricted inhibition of NF-κB, in Apolipoprotein E knockout (ApoE−/−) mice fed a high fat western diet resulted in greatly reduced size and severity of atherosclerotic lesions. Inhibition of NF-κB abrogated expression of adhesion molecules, diminished expression of cytokines and chemokines, and impaired macrophage recruitment to atherosclerotic plaques. These findings support a critical role of the endothelial NF-κB pathway in promoting the pathogenesis of atherosclerosis. Findings from the de Winther laboratory using macrophage-specific inhibition of the NF-κB pathway suggest that the role of NF-κB in this cell type is not as straightforward. Surprisingly, initial studies using LDL receptor deficient (LDLR−/−) mice with a macrophage-specific deletion of IκB kinase 2 (IKK2), showed increased atherosclerosis with more advanced lesions and more necrotic plaques. These results highlight the importance of NF-κB in the gene program promoting the resolution of inflammation. In contrast, a subsequent study using bone marrow from p50 deficient mice transplanted into irradiated LDLR−/− mice demonstrated that hematopoietic deficiency of the p50 subunit of NF-κB results in smaller atherosclerotic lesions with a near complete absence of foam cells. A more recent study in LDLR−/− mice transplanted with bone marrow from mice with myeloid-specific deletion of IκBα demonstrated larger and more advanced atherosclerotic lesions through enhanced leukocyte recruitment to plaques. These disparate results of NF-κB function in macrophages have yet to be fully reconciled. Despite the in vivo study of the role of the NF-κB pathway in atherosclerosis and vascular inflammation in ECs and macrophages, similar studies investigating this pathway in vascular SMCs have been lacking to date.

In this issue of Journal of the American Heart Association, Yoshida and colleagues investigate the cell autonomous role of NF-κB within SMCs by using SM22α Cre to generate mice with SMC-specific expression of a truncated form of IκB (IκBΔN) lacking 2 N-terminal phosphorylation sites. SMC-specific expression of IκBΔN results in selective sequestration of NF-κB in the cytoplasm of SMCs. Mice with SMC-specific inhibition of the NF-κB pathway displayed a
significant reduction in neointima, slower proliferation rate, and an attenuated inflammatory response after vascular injury as demonstrated by decreased expression of VCAM-1, ICAM-1, and CCL20. Down-regulation of SMC differentiation markers and myocardin is a hallmark feature of the phenotype switching of differentiated SMCs in response to vascular injury. SMC-selective inhibition of NF-κB resulted in attenuated repression of SMC differentiation factors, SM α-actin, SM22α, and SM myosin heavy chain (SMMHC) as well as myocardin. Mechanistically, the authors demonstrate that IL-1β-mediated decrease in expression of SMC differentiation markers and myocardin is dependent on NF-κB and is partially mediated by Kruppel-like Factor 4 (KLF4). Finally, detailed myocardin promoter analysis reveals consensus binding sites mediated by Kruppel-like Factor 4 (KLF4).

Interestingly, in SMCs, NF-κB acts as a direct transcriptional repressor of the myocardin promoter in response to vascular injury and inflammation. During vascular inflammation and atherosclerosis in other cell types, such as ECs and macrophages, NF-κB acts predominantly as a direct transcriptional activator via interaction with major coactivator proteins such as CREB-binding protein (CBP), p300, steroid receptor-coactivator-1 (SRC-1), and p300/CBP-associated factor (PCAF). This apparent unique tissue-specific transcriptional repression by NF-κB in SMCs in response to vascular injury warrants further investigation to elucidate the detailed molecular mechanisms.

Also very intriguing is the identification of KLF4 as a cooperative transcriptional inhibitory binding partner with NF-κB on the myocardin promoter in SMCs, resulting in the down-regulation of SMC differentiation markers. KLFs are a subgroup of the zinc finger family of transcription factors that have been shown to broadly regulate numerous physiological and pathological processes in many cell types and organ systems. Remarkably, in the past decade KLFs have been identified as atheroprotective factors in multiple cell types including ECs, macrophages, and SMCs. KLF2 and KLF4 are highly expressed in ECs and both have been implicated as “molecular switches” regulating endothelial health and disease by differentially controlling the expression of factors that confer antiinflammatory, antithrombotic, vasodilatory, and antiproliferative effects in ECs. One important mechanism of action of KLF2 and KLF4 in ECs is the inhibition of cytokine-mediated induction of cell adhesion molecules. In striking contrast to the observations of Yoshida and colleagues with KLF4 in SMCs, KLF2 and KLF4 in ECs inhibit NF-κB function by competing for the common coactivators p300 and PCAF, thereby serving as inhibitors of vascular inflammation. Notably, this function is independent of KLF DNA binding. More recently KLF11 has been shown to be a suppressor of endothelial inflammatory activation by a very similar NF-κB inhibitory mechanism.

KLF2 and KLF4 are also highly expressed in monocytes/macrophages where they have been shown to play important roles in monocyte differentiation, macrophage activation and polarization, and regulation of inflammatory signaling. As in ECs, a major mechanism of action of KLF2 and KLF4 in monocytes/macrophages is the inhibition of the NF-κB pathway. Importantly, in vivo studies from our group and others using the ApoE−/− and LDLR−/− models have established KLF2 and KLF4 as atheroprotective factors in both endothelial and myeloid cells. Taken together these findings suggest that interplay between NF-κB and KLFs is cell-type specific and is important for mediating the cellular response to vascular inflammation (see Figure). Future studies aimed at investigating the cell-specific mechanism that determines whether the interaction between KLFs and NF-κB is cooperative or inhibitory would be of great interest in the field.

Figure. Interplay between NF-κB and KLFs in atherosclerosis and vascular inflammation is cell type specific. Schematic diagram demonstrating antagonism between KLF4 and NF-κB in endothelial cells and monocytes/macrophages vs cooperation in smooth muscle cells. NF indicates nuclear factor; KLFs, Kruppel-like factors.
KLFs are also expressed and play key roles in SMC biology. Work from the Owens lab has outlined the importance of KLF4 in mediating the SMC response to vascular inflammation.11 Yoshida and colleagues highlight the necessity for cooperation between KLF4 and NF-κB in mediating the inhibition of myocardin in response to vascular injury.4 The authors choose to focus on KLF4 for their studies as KLF4 is induced in SMCs by IL-1β. Notably, KLF5 and KLF15 are 2 other KLFs that have been demonstrated to play key roles in mediating the SMC response to vascular inflammation11,22 and warrant investigation in this model. Finally, in order to truly assess the cell-autonomous role of NF-κB in SMCs in the pathogenesis of atherosclerosis, it will be important to cross mice with SMC-specific inhibition of the NF-κB pathway to the LDLR−/− or ApoE−/− mouse models of atherosclerosis. Along the same lines, similar in vivo studies with SMC-specific deletion of KLF4, KLF5, and KLF15 in atherosclerosis models have yet to be conducted. Such studies would be highly revealing and provide novel mechanistic insight into the pathogenesis of atherosclerosis, thereby potentially resulting in novel therapies for disease.

Sources of Funding
This work was supported in part by National Institutes of Health grants to Dr Simon (HL57506 MERIT Award) and Visconi Scholar Award to Dr Atkins.

Disclosures
None.

References
1. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32:2045–2051.
2. de Winther MP, Kanters E, Kraal G, Hofker MH. Nuclear factor kappaB signaling in arterogenesis. Arterioscler Thromb Vasc Biol 2005;25:904–914.
3. Baker RG, Hayden MS, Ghosh S. NF-kappaB, inflammation, and metabolic disease. Cell Metab. 2011;13:11–22.
4. Yoshida T, Yamashita M, Horimai C, Hayashi M. Smooth muscle-selective inhibition of nuclear factor-kappa B attenuates smooth muscle phenotype switching and neointima formation following vascular injury. J Am Heart Assoc. 2013;2:e002300.
5. Gareaus R, Kotsaki E, Xanthoulou S, van der Made I, Gijbels MJ, Kardakaris R, Polykratis A, Kollias G, de Winther MP, Pasparakis M. Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis. Cell Metab. 2008;8:372–383.
6. Kanters E, Pasparakis M, Gijbels MJ, Vergouwe MN, Partoun-Hendriks I, Fijneman RJ, Clausen BE, Forster I, Kockx MM, Rajewsky K, Kraal G, Hofker MH, de Winther MP. Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2003;112:1176–1185.
7. Kanters E, Gijbels MJ, van der Made I, Vergouwe MN, Heeringa P, Kraal G, Hofker MH, de Winther MP. Hematopoietic NF-kappaB1 deficiency results in small atherosclerotic lesions with an inflammatory phenotype. Blood. 2004;103:934–940.
8. Goossens P, Vergouwe MN, Gijbels MJ, Curfs DM, van Woezik JH, Hoeckema MA, Xanthoulou S, Leenen PJ, Rupe RA, Hofker MH, de Winther MP. Myeloid IkappaBalpha deficiency promotes atherogenesis by enhancing leukocyte recruitment to the plaques. PLoS One. 2011;6:e22327.
9. Xanthoulou S, Curfs DM, Hofker MH, de Winther MP. Nuclear factor kappaB signaling in macrophage function and atherogenesis. Curr Opin Lipidol. 2005;16:536–542.
10. McConnell BB, Yang VW. Mammalian Kruppel-like factors in health and disease. Physiol Rev. 2010;90:1337–1381.
11. Alati MA, Orasanu G, Tugal D, Lu Y, Jain MK. Kruppel-like factors and vascular inflammation: implications for atherosclerosis. Curr Atheroscler Rep. 2012; 14:438–449.
12. Atkins GB, Jain MK. Role of Kruppel-like transcription factors in endothelial biology. Circ Res. 2007;100:1686–1695.
13. SeriBanerjee S, Lim Z, Atkins GB, Greif DM, Rao RM, Kumar A, Feinberg MW, Chen Z, Simon DJ, Lusciniskas FW, Michel TM, Gimbrone MA Jr, Garcia-Cardenas G, Jain MK. KLF2 is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med. 2004;199:1305–1315.
14. Hamik A, Lin Z, Kumar A, Ballecs M, Sinha S, Katz J, Feinberg MW, Gerzseny RE, Edelman ER, Jain MK. Kruppel-like factor 4 regulates endothelial inflammation. J Biol Chem. 2007;282:13769–13779.
15. Fan Y, Guo Y, Zhang J, Subramaniam M, Song CZ, Urrutia R, Chen YE. Kruppel-like factor-11, a transcription factor involved in diabetes mellitus, suppresses endothelial cell activation via the nuclear factor-kappaB signaling pathway. Arterioscler Thromb Vasc Biol. 2012;32:2981–2988.
16. Das H, Kumar A, Lin Z, Patino WD, Hwang PM, Feinberg MW, Majumder PK, Jain MK. Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc Natl Acad Sci USA. 2006;103:6653–6658.
17. Mahabeleshwar GH, Kawanami D, Sharma N, Takami Y, Zhou G, Shi H, Nayan L, Jeyaraj D, Grealy R, White M, McManus R, Ryan T, Leahy P, Lim Z, Haldar SM, Atkins GB, Wong HR, Lingrel JB, Jain MK. The myeloid transcription factor KLF2 regulates the host response to polymicrobial infection and endotoxic shock. Immunity. 2011;34:715–728.
18. Atkins GB, Wang Y, Mahabeleshwar GH, Shi H, Gao H, Kawanami D, Natesan V, Lin Z, Simon DJ, Jain MK. Hemizygous deficiency of Kruppel-like factor 2 augments experimental atherosclerosis. Circ Res. 2008;103:690–693.
19. Zhou G, Hamik A, Nayak L, Tian H, Shi H, Lu Y, Sharma N, Liao X, Haldar SM, Boerboom L, Feaver RE, Gao H, Desai A, Schmaier A, Gerson SL, Wang Y, Atkins GB, Blackman BR, Simon DJ, Jain MK. Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice. J Clin Invest. 2012;122:4727–4731.
20. Lingrel JB, Pichler-Roberts R, Basford JE, Manoharan P, Neumann J, Konaniah ES, Srinivasan R, Bogdanov VY, Hui DY. Myeloid-specific Kruppel-like factor 2 inactivation increases macrophage and neutrophil adhesion and promotes atherosclerosis. Circ Res. 2012;110:1294–1302.
21. Sharma N, Lu Y, Zhou G, Liao X, Kapil P, Anand P, Mahabeleshwar GH, Stamler JS, Jain MK. Myeloid Kruppel-like factor 4 deficiency augments atherosclerosis in ApoE−/− mice—brief report. Arterioscler Thromb Vasc Biol. 2012;32:2836–2838.
22. Lu Y, Haldar S, Croce K, Wang Y, Sakuma M, Morooka T, Wang B, Jeyaraj D, Gray S], Simon DJ, Jain MK. Kruppel-like factor 15 regulates smooth muscle cell response to vascular injury—brief report. Arterioscler Thromb Vasc Biol. 2010; 30:1550–1552.

Key Words: editorials • atherosclerosis • KLF • NF-κB • vascular inflammation